Litcius/Paper detail

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial

Τheodoros Karampitsakos, Ουρανία Παπαϊωάννου, Panagiota Tsiri, Matthaios Katsaras, Andreas Katsimpris, Andreas P. Kalogeropoulos, Elli Malakounidou, Eirini Zarkadi, Georgios Tsirikos, Vasiliki V. Georgiopoulou, Vasilina Sotiropoulou, Electra Koulousousa, Charikleia Chourpiliadi, Apostolos Matsioulas, Maria Lagadinou, Fotios Sampsonas, Karolina Akinosoglou, Markos Marangos, Αrgyris Τzouvelekis

2022Clinical Microbiology and Infection45 citationsDOIOpen Access PDF

Topics & Concepts

TocilizumabMedicineMechanical ventilationRandomized controlled trialHazard ratioInternal medicineSurgeryConfidence intervalDiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial | Litcius